Clinical trial · Interventional
ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Craniopharyngioma Patients
NCT07177482CI-TRIAL-00095314recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate 68Ga-MY6349, an immune-PET tracer targeting trophoblast cell surface antigen 2 (Trop2), for the noninvasive diagnosis of craniopharyngioma in vivo.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Craniopharyngioma | Craniopharyngioma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-MY6349 PET/CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-MY6349 PET/CT
- description
- Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET/CT imaging within the specified time.
- interventionNames
- Diagnostic Test: 68Ga-MY6349 PET/CT
Primary outcomes (1)
- measure
- Standardized uptake value of 68Ga-MY6349 in PET imaging of craniopharyngioma
- timeFrame
- Within 1 week after PET imaging.
- description
- The semiquantitative analysis will be performed by the same person for all the cases, and the standardized uptake value (SUV) of the tracer in craniopharyngioma will be measured.
Secondary outcomes (1)
- measure
- Evaluate the feasibility of PET/CT imaging with 68Ga-MY6349 for the non-invasive assessment of Trop2 expression in craniopharyngioma.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion criteria: * must be able to provide a written informed consent * radiologically presumed and/or histologically confirmed craniopharyngioma scheduled for resection * adequate clinical condition (Karnofsky performance status ≥70) Exclusion criteria: * concomitant major central nervous system disorders * severe hepatic or renal dysfunction * history of severe allergy or hypersensitivity to intravenous radiographic contrast agents * claustrophobia precluding PET/CT or MRI examinations * pregnancy or breastfeeding
References
Publications (0)
Data not yet available
No reference posted for this study.